Labcorp, PathAI Extend Their Collaboration

Labcorp is expanding its collaboration with PathAI to deploy AISight Dx1 across its national network of anatomic pathology labs and hospital collaborations. The cloud-based technology allows pathologists to view and manage slides digitally and use artificial intelligence (AI) to support key steps in the diagnostic process.

“Labcorp is committed to building a modern, AI-powered infrastructure that sets a new standard for efficiency, collaboration, and innovation in pathology,” Labcorp Chief Scientific Officer Dr. Marcia Eisenberg said. “PathAI’s technology allows us to scale digital pathology nationwide and integrate AI insights into routine care—delivering faster, more consistent results for patients and providers.”

Labcorp will deploy the U.S. Food and Drug Administration (FDA)-cleared digital pathology platform, AISight Dx, across its anatomic pathology labs and hospital collaborations, enabling fully digital workflows for case management, slide review, collaboration, and annotation. The platform also integrates AI-powered image analysis, secure storage, and system connectivity to deliver faster turnaround, greater efficiency, reliable quality, and improved collaboration. Labcorp will also incorporate digital pathology workflows in support of its precision medicine products.

“Labcorp’s leadership in diagnostics makes them an ideal partner in our mission to modernize pathology through software and AI,” PathAI Co-Founder/CEO Dr. Andy Beck stated. “The deployment of AISight Dx across Labcorp’s network brings high-quality, efficient digital pathology to a national scale.”

The expansion builds on Labcorp’s 2019 strategic investment in PathAI, a collaboration that has since advanced to include AI-driven clinical trial support and validation of novel AI-pathology solutions.

Labcorp provides laboratory services that help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The company provides insights and advanced science to improve health and improve lives through diagnostics and drug development laboratory capabilities. Labcorp’s nearly 71,000 employees serve clients in approximately 100 countries, provide support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients worldwide.

AISight Dx is FDA-cleared for primary diagnosis in the United States and CE-IVD marked for primary diagnosis in the European Economic Area, United Kingdom, and Switzerland.